Omada Health Inc. (NASDAQ:OMDA) shares are up in Friday’s premarket session following the announcement of its new GLP-1 Flex Care program, which aims to help employers provide access to GLP-1 medications for obesity.
The company on Thursday reported fourth-quarter results that beat expectations and issued upbeat guidance for 2026.
Employer GLP-1 Support
Omada Health’s GLP-1 Flex Care offering enables employers to manage the costs of GLP-1 medications while providing necessary clinical oversight.
The program, announced on Thursday, aims to address the growing demand among employees for these medications, which have seen notable increases in persistence rates among users, with 67% remaining on medication after one year, compared to 47-49% in similar studies.
The initiative is designed to help employers navigate the complexities of medication coverage while ensuring employees receive the necessary support and oversight.
By allowing members to purchase medications independently through cash-pay channels, Omada Health provides a financially sustainable pathway for employers to support their workforce’s health needs.
Earnings Surpass Expectations
Omada Health on Thursday reported fourth-quarter earnings of 8 cents per share, beating the consensus of a loss of 3 cents.
Sales reached $75.85 million, up 58% year over year, beating the consensus of $69.67 million.
Omada said it supported more than 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024
“We demonstrated GLP‑1 companion support innovation, advanced our member‑facing AI capabilities, and introduced meaningful program expansions—all designed to support our members in achieving durable health improvements…,” said Sean Duffy, co‑founder and CEO of Omada Health
Omada Health forecasts fiscal 2026 sales of $312 million-$322 million versus the consensus of $311.41 million.
Omada Health Technical Analysis
The stock is currently trading 31.6% above its 20-day simple moving average (SMA) and 11.5% above its 50-day SMA, indicating short-term strength.
However, it is trading 9.1% below its 100-day SMA, suggesting some longer-term weakness.
The RSI is at 56.70, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at -0.2761, with the signal line at -0.6547, suggesting a bullish momentum as the MACD is above the signal line.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while the stock is not in an overbought condition, there is potential for upward movement.
- Key Resistance: $17.00
- Key Support: $14.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $24.18. Recent analyst moves include:
- Barclays: Overweight (Lowers Target to $17.00) (Mar. 3)
- Needham: Buy (Maintains Target to $28.00) (Jan. 22)
- Wells Fargo: Initiated with Equal-Weight (Target $17.00) (Jan. 9)
OMDA Price Action: Omada Health shares were up 10.51% at $15.03 during premarket trading on Friday, according to Benzinga Pro data.
Photo by David Esser via Shutterstock
